Drug Search Results
More Filters [+]

Ezatiostat

Alternative Names: ezatiostat
Latest Update: 2023-03-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: GSTA Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: MabVax Holdings
Company Location: SAN DIEGO CA 92121
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ezatiostat

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Preleukemia|Neutropenia|Myelodysplastic Syndrome|Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TLK199.2103

P2

Terminated

Neutropenia

2013-05-01

TLK199.2107

P2

Terminated

Myelodysplastic Syndrome|Preleukemia

2013-02-01

TLK199.2108

P2

Terminated

Myelodysplastic Syndrome|Preleukemia

2013-02-01

TLK199.2101

P2

Completed

Preleukemia|Myelodysplastic Syndrome

2011-07-01

Recent News Events